AURA•benzinga•May 15, 2025 at 10:20 AM

As Of March 31, 2025, Aura Biosciences Had Cash And Cash Equivalents And Marketable Securities Of $128M, Sufficient To Fund Its Operations Into 2H Of 2026

No summary available.

Read the full article from the original source for complete details and context.

Article published on May 15, 2025 by benzinga